1. Introduction {#sec1-medicina-55-00298}
===============

Tuberculosis (TB) is a chronic infectious disease caused by the bacillus *Mycobacterium tuberculosis* (MTB). It remains a serious public global health problem. According to the World Health Organization (WHO) report, there were an estimated 10.4 million new cases of TB worldwide and approximately 1.3 million deaths in 2016 \[[@B1-medicina-55-00298]\]. Approximately one-third of the general population is currently infected with Mtb, and nearly 5--10% of these infected individuals will progress to active TB \[[@B2-medicina-55-00298],[@B3-medicina-55-00298]\]. Mounting evidence has proposed that host genetic factors play an important role in determining inter-individual difference in susceptibility to TB \[[@B4-medicina-55-00298],[@B5-medicina-55-00298],[@B6-medicina-55-00298]\].

The human *P2X7* gene is mapped to chromosome 12 (12q24.31). It encodes cell-surface nucleotide receptors called P2X7 receptor (P2X7R) \[[@B7-medicina-55-00298]\]. The P2X7R, a ligand-gated cation channel, is highly expressed on macrophages and other immune cells \[[@B8-medicina-55-00298]\]. Activation of P2X7R by extracellular adenosine triphosphate (eATP) causes immediate opening of a cation selective channel, permitting the influx of Ca^2+^ and Na^+^ and the efflux of K^+^ \[[@B9-medicina-55-00298]\]. In M. tuberculosis infection, activation of the P2X7R promotes a range of signaling cascades leading to the apoptosis of MTB-infected macrophages \[[@B10-medicina-55-00298],[@B11-medicina-55-00298]\].

The *P2X7R* gene is indeed polymorphic. The precise correlation between the *P2X7* polymorphisms and susceptibility to TB is not completely documented. Several single nucleotide polymorphisms (SNPs) have been revealed that affect the function of this receptor which cause P2X7R loss-of-function (LOF) or gain-of-function (GOF) \[[@B8-medicina-55-00298]\]. Many studies have inspected the association between *P2X7* polymorphisms and risk of tuberculosis in various populations, but the findings were inconsistent \[[@B12-medicina-55-00298],[@B13-medicina-55-00298],[@B14-medicina-55-00298],[@B15-medicina-55-00298],[@B16-medicina-55-00298],[@B17-medicina-55-00298],[@B18-medicina-55-00298],[@B19-medicina-55-00298],[@B20-medicina-55-00298],[@B21-medicina-55-00298],[@B22-medicina-55-00298],[@B23-medicina-55-00298],[@B24-medicina-55-00298],[@B25-medicina-55-00298],[@B26-medicina-55-00298],[@B27-medicina-55-00298],[@B28-medicina-55-00298],[@B29-medicina-55-00298],[@B30-medicina-55-00298],[@B31-medicina-55-00298],[@B32-medicina-55-00298],[@B33-medicina-55-00298],[@B34-medicina-55-00298],[@B35-medicina-55-00298]\]. So we conducted an updated meta-analysis of all available eligible case-control studies published to date, focusing on the association between *P2X7* polymorphisms and tuberculosis risk.

2. Methods {#sec2-medicina-55-00298}
==========

2.1. Literature Search {#sec2dot1-medicina-55-00298}
----------------------

The PubMed, Web of Science, Scopus, and Google scholar databases for all potentially eligible research articles up to November 2018 on the relationship between *P2X7* polymorphisms and TB risk were searched. The search key words used were "*P2X7* or P2X7R" and "tuberculosis" and "polymorphism or variant". [Figure 1](#medicina-55-00298-f001){ref-type="fig"} shows the process of recognizing eligible studies. The inclusion criteria were as follows: case-control studies focusing on the association between *P2X7* polymorphisms and TB risk; the frequencies distribution of alleles and genotypes in patients and controls can be extracted. The exclusion criteria were studies that are not associated with *P2X7* polymorphisms and TB risk; overlapping data, conference papers, reviews, meta-analyses; no sufficient data reported.

2.2. Data Extraction {#sec2dot2-medicina-55-00298}
--------------------

Two investigators independently inspected and evaluated the articles for eligibility according to inclusion and exclusion criteria. The following data were recorded from the selected studies such as the first author's name, publication year, ethnicity, genotyping methods, genotype and allelic profile, as well as the source of controls.

2.3. Statistical Analysis {#sec2dot3-medicina-55-00298}
-------------------------

The chi-square test was used to check whether genotypes within the controls conformed to the Hardy-Weinberg equilibrium (HWE). We calculated the pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) to assess the association between the *P2X7* polymorphisms and TB susceptibility. The significance of the pooled OR was determined by the Z-test, and a *p*-value less than 0.05 was considered significant. Heterogeneity between the studies was estimated by Q statistic and the I^2^ test. *p* \< 0.10 designated significant heterogeneity. If heterogeneity did not exist, a fixed-effects model was used to calculate the pooled ORs; otherwise, a random-effects model was utilized.

Publication bias was inspected with the funnel plot and an asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was further measured using Egger's linear regression test. *p* value \< 0.05 was considered a significant publication bias. Sensitivity analysis was done by neglecting each study in turn to assess the quality and consistency of the results. All statistical analyses were executed using STATA v14.1 software (College Station, TX, USA).

3. Results {#sec3-medicina-55-00298}
==========

3.1. Study Characteristics {#sec3dot1-medicina-55-00298}
--------------------------

Through a comprehensive literature search and selection based on the inclusion criteria, 59 relevant case-control studies from 24 selected articles \[[@B12-medicina-55-00298],[@B13-medicina-55-00298],[@B14-medicina-55-00298],[@B15-medicina-55-00298],[@B16-medicina-55-00298],[@B17-medicina-55-00298],[@B18-medicina-55-00298],[@B19-medicina-55-00298],[@B20-medicina-55-00298],[@B21-medicina-55-00298],[@B22-medicina-55-00298],[@B23-medicina-55-00298],[@B24-medicina-55-00298],[@B25-medicina-55-00298],[@B26-medicina-55-00298],[@B27-medicina-55-00298],[@B28-medicina-55-00298],[@B29-medicina-55-00298],[@B30-medicina-55-00298],[@B31-medicina-55-00298],[@B32-medicina-55-00298],[@B33-medicina-55-00298],[@B34-medicina-55-00298],[@B35-medicina-55-00298]\] were included in the pooled analysis. There were 30 studies with 5247 cases and 7614 controls on rs3751143 (1513A \> C), 19 studies with 3235 cases and 4685 controls on rs2393799 (−762 C \> T), 3 studies with 2185 cases and 2107 controls on rs1718119 (Thr348Ala), 3 studies with 1994 cases and 2037 controls on rs208294 (His155Tyr), 2 studies with 2000 cases and 2006 controls on rs7958311, 2 studies with 1853 cases and 1797 controls on rs2230911 included into meta-analysis. The main characteristics of included studies are shown in [Table 1](#medicina-55-00298-t001){ref-type="table"}.

3.2. Main Analysis Results {#sec3dot2-medicina-55-00298}
--------------------------

The Forest plots were applied to show meta-analysis results for each genetic model. Overall, the rs3751143 variant significantly increased the risk of TB in heterozygous codominant (OR = 1.44, 95% CI = 1.17--1.78, *p* = 0.0006, AC vs. AA), homozygous codominant (OR = 1.87, 95% CI = 1.40--2.49, *p* = 0.0004, CC vs. AA), dominant (OR = 1.50, 95% CI = 1.22--1.85, *p* = 0.0002, AC + CC vs. AA), recessive (OR = 1.61, 95% CI = 1.25--2.07, *p* = 0.001, CC vs. AC + AA), and allele (OR = 1.41, 95% CI = 1.19--1.67, *p* \< 0.0001, C vs. A) genetic models ([Table 2](#medicina-55-00298-t002){ref-type="table"} and [Figure 2](#medicina-55-00298-f002){ref-type="fig"}).

No significant association was found between P2X7 rs2393799, rs1718119, rs208294, rs7958311, and rs2230911 polymorphisms and TB risk ([Table 2](#medicina-55-00298-t002){ref-type="table"}).

3.3. Subgroup Analysis Results {#sec3dot3-medicina-55-00298}
------------------------------

Stratified analysis was achieved ([Table 3](#medicina-55-00298-t003){ref-type="table"}). The findings proposed that rs3751143 polymorphism increased the risk of pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) in all genetic models. Besides, this polymorphism only contributes to the risk of TB in the Asian population, but not in the Caucasian population ([Table 3](#medicina-55-00298-t003){ref-type="table"}). The rs2393799 polymorphism was not associated with the risk of TB in the Asian population ([Table 3](#medicina-55-00298-t003){ref-type="table"}).

3.4. Heterogeneity and Publication Bias {#sec3dot4-medicina-55-00298}
---------------------------------------

In our study, relatively obvious heterogeneities existed under all five genetic models for rs3751143 and rs2393799 ([Table 2](#medicina-55-00298-t002){ref-type="table"}). For rs1718119, heterogeneities were not observed under all genetic models. For rs208294, heterogeneities were not observed under heterozygous codominant and recessive genetic models. For rs7958311, heterogeneities were not observed under heterozygous codominant and for rs2230911 variant, heterogeneities were not observed under heterozygous codominant and dominant models.

Begg's tests were done with funnel plot to assess publication bias. Publication bias was found for rs3751143 under five genetic models ([Table 2](#medicina-55-00298-t002){ref-type="table"} and [Figure 3](#medicina-55-00298-f003){ref-type="fig"}).

The Begg's tests indicated no evidence of publication bias for rs2393799, rs1718119, and rs208294 ([Table 2](#medicina-55-00298-t002){ref-type="table"}) under all genetic models.

3.5. Sensitivity Analysis {#sec3dot5-medicina-55-00298}
-------------------------

To better inspect the impact of individual study on the pooled OR, we performed sensitivity analysis through deleting each study one by one. Outcomes indicated that ORs were not statistically influenced in all genetic models for rs3751143 ([Figure 4](#medicina-55-00298-f004){ref-type="fig"}), as well as for rs2393799, showing that our results are stable and reliable.

4. Discussion {#sec4-medicina-55-00298}
=============

Mounting evidence proposed that host genetic factors are implicated in tuberculosis susceptibility \[[@B4-medicina-55-00298],[@B6-medicina-55-00298]\]. The P2X7R is highly expressed on macrophages and other immune cells \[[@B8-medicina-55-00298]\]. It is a key molecule in the clearance of MTB in macrophages by adenosine triphosphate (ATP)-induced apoptosis of macrophage \[[@B8-medicina-55-00298],[@B10-medicina-55-00298]\]. *P2X7* is polymorphic and several studies investigated the impact of *P2X7* polymorphisms on predisposition to TB \[[@B12-medicina-55-00298],[@B13-medicina-55-00298],[@B14-medicina-55-00298],[@B15-medicina-55-00298],[@B16-medicina-55-00298],[@B17-medicina-55-00298],[@B18-medicina-55-00298],[@B19-medicina-55-00298],[@B20-medicina-55-00298],[@B21-medicina-55-00298],[@B22-medicina-55-00298],[@B23-medicina-55-00298],[@B24-medicina-55-00298],[@B25-medicina-55-00298],[@B26-medicina-55-00298],[@B27-medicina-55-00298],[@B28-medicina-55-00298],[@B29-medicina-55-00298],[@B30-medicina-55-00298],[@B31-medicina-55-00298],[@B32-medicina-55-00298],[@B33-medicina-55-00298],[@B34-medicina-55-00298],[@B35-medicina-55-00298]\]. But these studies failed to reach a consistent conclusion. Therefore, to provide a comprehensive and reliable conclusion, we conducted the present meta- analysis to increase the statistical power of the association. Our findings suggest the *P2X7* rs3751143 (Glu498Ala) polymorphism significantly increased the risk of overall TB. Stratified analysis of this polymorphism significantly increased the risk of PTB and EPTB. Also, the rs3751143 polymorphism increased the risk of TB in the Asian population. Findings did not support an association between rs2393799 (−762 C \> T), rs1718119 (Thr348Ala), rs208294 (His155Tyr), rs7958311 (Arg270His), and rs2230911(Thr357Ser) polymorphisms and TB risk.

Ge et al. \[[@B36-medicina-55-00298]\] performed a meta-analysis (*n =* 10) on the association between *P2X7* rs3751143 polymorphism and PTB risk and found that this variant significantly increased the risk of PTB. Another meta-analysis (*n =* 11) performed by Alshammari et al. \[[@B37-medicina-55-00298]\] showed no significant association between rs3751143 polymorphism and risk of TB. Stratified analysis revealed an association between this variant and the risk of TB in the Asian population. The results of a meta-analysis of 8 studies indicated that rs3751143 polymorphism significantly increased the risk of EPTB \[[@B38-medicina-55-00298]\]. Another meta-analysis of 9 studies conducted by Wu et al. \[[@B39-medicina-55-00298]\] revealed that rs3751143 significantly increased the risk of TB. A meta-analysis published by Yi et al. \[[@B40-medicina-55-00298]\] on the association between rs2393799 (−762 C \> T) polymorphism and TB susceptibility indicated that this variant is associated with TB risk. Our meta-analysis has more advantages than previous meta-analyses. We included a higher number of relevant published studies. Besides, we evaluated 6 polymorphisms in this meta-analysis.

Several polymorphisms have been described that cause P2X7R loss-of-function (LOF) or gain-of-function (GOF) \[[@B8-medicina-55-00298]\]. The common polymorphism of *P2X7* is rs3751143 (A1513C; Glu498Ala) polymorphism located in exon 13, accountable for LOF. This polymorphism affects the sensitivity of P2X7R to ATP and may contribute to increased susceptibility to MTB infection in humans \[[@B13-medicina-55-00298],[@B14-medicina-55-00298],[@B41-medicina-55-00298]\]. The findings of the present meta-analysis support an association between rs3751143 polymorphism and the risk of TB. Another LOF polymorphism is rs2393799 (−762 C \> T), which is located in the promoter of *P2X7* and decrease the expression of P2X7R. The relationship between the rs2393799 polymorphism and susceptibility to TB is still debated \[[@B12-medicina-55-00298],[@B13-medicina-55-00298],[@B14-medicina-55-00298],[@B17-medicina-55-00298],[@B18-medicina-55-00298],[@B19-medicina-55-00298],[@B21-medicina-55-00298],[@B23-medicina-55-00298],[@B27-medicina-55-00298],[@B28-medicina-55-00298],[@B29-medicina-55-00298],[@B31-medicina-55-00298],[@B32-medicina-55-00298],[@B33-medicina-55-00298],[@B34-medicina-55-00298]\], and pooled analysis of all available data did not support an association between this variant and susceptibility to TB. The rs208294 (489 C \> T; His155Tyr) is GOF polymorphism. This polymorphism increases the affinity of P2X7R to ATP \[[@B42-medicina-55-00298]\]. Limited studies investigated the impact of this polymorphism on TB susceptibility \[[@B14-medicina-55-00298],[@B30-medicina-55-00298],[@B34-medicina-55-00298]\]. Pooled analysis revealed no evidence of association between this variant and TB risk.

Up until now, only 3 studies investigated the association between rs1718119 (1068 G \> A; Thr348Ala) polymorphism and TB risk \[[@B30-medicina-55-00298],[@B31-medicina-55-00298],[@B34-medicina-55-00298]\]. Our findings did not support an association between this polymorphism and TB risk.

*Porphyromonas gingivalis*, a bacterial carcinogen, plays a key role in cancer development by inhibiting apoptosis through several mechanisms. It has been shown that this bacterium secretes an anti-apoptotic enzyme nucleoside diphosphate kinase (NDK) which cleaves ATP and prevents proapoptotic P2X7 receptor activation, consequently modulating ATP/P2X7-signaling pathway \[[@B43-medicina-55-00298]\]. It has been proposed that MTB secrete NDK, which act as a Rho-GTPase-activating protein (Rho-GAP), and covert Guanosine triphosphate (GTP)-bound active form to guanosine diphosphate (GDP)-bound inactive form, eventually facilitating its pathogenesis \[[@B44-medicina-55-00298]\].

Some limitations of our meta-analysis should be acknowledged. Firstly, heterogeneity between studies was evident, which might distort the conclusion of this meta-analysis. Heterogeneity may be partly arising in the differences of ethnicities. Secondly, the sample sizes for some polymorphisms were small. Therefore, the results of this meta-analysis should be interpreted with caution.

Despite these limitations, however, there are still some advantages to having done this meta-analysis. First, this meta-analysis involved more studies than the previous meta-analyses, so the statistical power of our study is higher than the published meta-analysis. Second, we evaluated six polymorphisms of *P2X7*.

5. Conclusions {#sec5-medicina-55-00298}
==============

Overall, our meta-analysis proposed that *P2X7* rs3751143 polymorphism may serve as a risk factor for TB in the Asian population. However, further well-designed studies with large sample sizes are necessary to confirm our findings.
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![Flow chart illustrates the detailed study selection process of this meta-analysis.](medicina-55-00298-g001){#medicina-55-00298-f001}

![The forest plot for association between P2X7 rs3751143 polymorphism and tuberculosis risk under allelic genetic model (C vs. A).](medicina-55-00298-g002){#medicina-55-00298-f002}

![The funnel plot for the test of publication bias. The funnel plot for rs3751143 polymorphism under allele genetic model (C vs. A).](medicina-55-00298-g003){#medicina-55-00298-f003}

![Sensitivity analyses for studies on P2X7 rs3751143 polymorphism and the risk of tuberculosis for C vs. A.](medicina-55-00298-g004){#medicina-55-00298-f004}
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###### 

Characteristics of all studies included in the meta-analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author    Year   Country          Ethnicity        TB      Source of Control   Genotyping Method   Case/Control   Cases   Controls   HWE (*p*)                                                 
  --------------- ------ ---------------- ---------------- ------- ------------------- ------------------- -------------- ------- ---------- ----------- ------ ------ ----- ----- ----- ------ ------ ---------
  Amiri           2018   Iran             Asian            PTB     PB                  PCR-RFLP            100/100        76      21         3           173    27     40    58    2     138    62     \<0.001

  Ben-Selma       2011   Tunisia          African          PTB     HB                  PCR-RFLP            168/150        130     34         4           294    42     104   40    6     248    52     0.395

  Ben-Selma       2011   Tunisia          African          EPTB    HB                  PCR-RFLP            55/150         19      23         13          61     49     104   40    6     248    52     0.395

  Chaudhary       2018   India            Asian            PTB     PB                  ARMS-PCR            145/247        63      73         9           199    91     141   95    11    377    117    0.315

  Chaudhary       2018   India            Asian            EPTB    PB                  ARMS-PCR            100/247        42      42         16          126    74     141   95    11    377    117    0.315

  De              2017   India            Asian            PTB     PB                  PCR-RFLP            56/60          26      18         12          70     42     36    21    3     93     27     0.978

  Fernando        2007   Southeast Asia   Asian            PTB     PB                  TaqMan              56/167         34      17         5           85     27     105   55    7     265    69     0.952

  Fernando        2007   Southeast Asia   Asian            EPTB    PB                  TaqMan              30/167         9       17         4           35     25     105   55    7     265    69     0.952

  Fernando        2007   Australia        Caucasian        PTB     PB                  TaqMan              49/102         28      21         0           77     21     64    34    4     162    42     0.845

  Fernando        2007   Australia        Caucasian        EPTB    PB                  TaqMan              50/102         18      28         4           64     36     64    34    4     162    42     0.845

  Li              2002   Gambia           African          PTB     HB                  PCR-RFLP            325/297        261     58         6           580    70     256   37    4     549    45     0.057

  Mokrousov       2008   Russia           Caucasian        PTB     HB                  PCR-RFLP            188/126        120     59         9           299    77     96    27    3     219    33     0.511

  Nino-Moreno     2007   México           Mixed            PTB     HB                  PCR-RFLP            94/110         53      33         8           139    49     70    38    2     178    42     0.215

  Ozdemir         2014   Turkey           Asian            PTB     PB                  PCR-RFLP            71/160         44      18         9           106    36     76    63    21    215    105    0.176

  Ozdemir         2014   Turkey           Asian            EPTB    PB                  PCR-RFLP            89/160         47      34         8           128    50     76    63    21    215    105    0.176

  Sambasivan      2010   India            Asian            PTB     HB                  PCR-RFLP            156/100        89      55         12          233    79     71    21    8     163    37     0.002

  Shamsi          2016   Iran             Asian            PTB     HB                  PCR-RFLP            100/100        33      66         1           132    68     83    16    1     182    18     0.817

  Sharma          2010   India            Asian            PTB     PB                  T-ARMS-PCR          181/177        102     75         4           279    83     126   48    3     300    54     0.515

  Sharma          2010   India            Asian            EPTB    PB                  T-ARMS-PCR          23/177         8       13         2           29     17     126   48    3     300    54     0.515

  Singla          2012   India            Asian            PTB     PB                  PCR-RFLP            286/392        162     112        12          436    136    258   123   11    639    145    0.420

  Singla          2012   India            Asian            EPTB    PB                  PCR-RFLP            71/392         45      22         4           112    30     258   123   11    639    145    0.420

  Souza de Lima   2016   Brazil           South American   PTB     HB                  TaqMan              288/287        170     95         23          435    141    184   89    14    457    117    0.450

  Taype           2010   Peru             Caucasian        PTB     HB                  PCR-RFLP            498/513        352     130        16          834    162    347   149   17    843    183    0.838

  Taype           2010   Peru             Caucasian        EPTB    HB                  PCR-RFLP            121/513        82      37         2           201    41     347   149   17    843    183    0.838

  Tekin           2010   Turkey           Caucasian        EPTB    HB                  PCR-RFLP            74/192         39      28         7           106    42     141   46    5     328    56     0.595

  Velayati        2013   Iran             Asian            PTB     HB                  PCR- RFLP           79/50          42      35         2           119    39     37    12    1     86     14     0.981

  Wu              2015   China            Asian            PTB     PB                  PCR-RFLP            103/87         33      49         21          115    91     51    27    9     129    45     0.075

  Xiao            2009   China            Asian            PTB     HB                  PCR-RFLP            41/384         21      18         2           60     22     221   119   44    561    207    \<0.001

  Xiao            2009   China            Asian            EPTB    HB                  PCR-RFLP            55/384         30      19         6           79     31     221   119   44    561    207    \<0.001

  Zheng           2017   China            Asian            PTB     PB                  TaqMan              1595/1521      972     551        72          2495   695    900   544   77    2344   698    0.655

  rs2393799\                                                                                                              CC      CT         TT          C      T      CC    CT    TT    C      T      
  C \> T                                                                                                                                                                                               

  Amiri           2018   Iran             Asian            PTB     PB                  PCR-RFLP            100/100        8       88         4           104    96     4     95    1     103    97     \<0.001

  Bahari          2013   Iran             Asian            PTB     PB                  ARMS-PCR            150/150        71      54         25          196    104    104   40    6     248    52     0.395

  Ben-Selma       2011   Tunisia          African          PTB     HB                  ARMS-PCR            168/150        16      57         95          89     247    14    51    85    79     221    0.130

  Ben-Selma       2011   Tunisia          African          EPTB    HB                  ARMS-PCR            55/150         4       15         36          23     87     14    51    85    79     221    0.130

  Chaudhary       2018   India            Asian            PTB     PB                  ARMS-PCR            145/247        62      67         16          191    99     101   111   35    313    181    0.614

  Chaudhary       2018   India            Asian            EPTB    PB                  ARMS-PCR            100/247        44      48         8           136    64     101   111   35    313    181    0.614

  Li              2002   Gambia           African          PTB     HB                  PCR-RFLP            323/347        23      118        182         164    482    44    140   163   228    466    0.111

  Mokrousov       2008   Russia           Caucasian        PTB     HB                  ARMS                190/127        86      87         17          259    121    65    46    16    176    78     0.093

  Nino-Moreno     2007   México           Mixed            PTB     HB                  ARMS                92/110         8       32         52          48     136    15    44    51    74     146    0.275

  Sambasivan      2010   India            Asian            PTB     HB                  PCR-RFLP            156/100        38      88         30          164    148    15    49    36    79     121    0.801

  Shamsi          2016   Iran             Asian            PTB     HB                  PCR-RFLP            100/100        1       99         0           101    99     6     93    1     105    95     \<0.001

  Singla          2012   India            Asian            PTB     PB                  ARMS                286/392        143     115        28          401    171    231   143   18    605    179    0.485

  Singla          2012   India            Asian            EPTB    PB                  ARMS                71/392         40      25         6           105    37     231   143   18    605    179    0.485

  Songane         2012   Indonesia        Asian            PTB     PB                  MassARRAY           842/844        181     413        248         775    909    177   412   255   766    922    \<0.001

  Velayati        2013   Iran             Asian            PTB     HB                  ARMS                79/50          10      67         2           87     71     3     47    0     53     47     \<0.001

  Wu              2015   China            Asian            PTB     PB                  PCR-RFLP            103/87         35      47         21          117    89     9     30    48    48     126    0.202

  Xiao            2009   China            Asian            PTB     HB                  ARMS                38/384         23      11         4           57     19     208   135   41    551    217    0.009

  Xiao            2009   China            Asian            EPTB    HB                  ARMS                58/384         40      12         6           92     24     208   135   41    551    217    0.009

  Zhou            2018   China            Asain            EPTB    HB                  Mass Spectrometry   179/324        81      77         21          239    119    122   143   59    387    261    0.137

  rs1718119\                                                                                                              GG      AG         AA          G      A      GG    AG    AA    G      A      
  G \> A                                                                                                                                                                                               

  Bahari          2013   Iran             Asian            PTB     PB                  T-ARMS-PCR          150/150        63      72         15          198    102    66    69    15    201    99     0.622

  Zheng           2017   China            Asian            PTB     PB                  TaqMan              1568/1454      1090    440        38          2620   516    978   417   59    2373   535    0.087

  Zhu             2016   China            Asian            PTB     HB                  MassARRAY           467/503        372     91         4           835    99     412   89    2     913    93     0.222

  rs208294\                                                                                                               GG      AG         AA          G      A      GG    AG    AA    G      A      
  G \> A                                                                                                                                                                                               

  Chaudhary       2018   India            Asian            Mixed   PB                  PCR-RFLP            245/246        56      147        42          259    231    49    143   54    241    251    0.011

  Zheng           2017   China            Asian            PTB     PB                  TaqMan              1570/1467      597     732        241         1926   1214   578   679   210   1835   1099   0.642

  Zhou            2018   China            Asian            EPTB    HB                  Mass\               179/324        22      80         77          124    234    70    145   109   285    363    0.099
                                                                                       Spectrometry                                                                                                    

  rs7958311\                                                                                                              GG      AG         AA          G      A      GG    AG    AA    G      A      
  G \> A                                                                                                                                                                                               

  Zheng           2017   China            Asian            PTB     PB                  TaqMan              1533/1503      402     797        334         1601   1465   396   775   332   1567   1439   0.199

  Zhu             2016   China            Asian            PTB     HB                  MassARRAY           467/503        114     215        138         443    491    137   262   104   536    470    0.300

  rs2230911\                                                                                                              CC      CG         GG          C      G      CC    CG    GG    C      G      
  C \> G                                                                                                                                                                                               

  Souza de Lima   2016   Brazil           South American   PTB     HB                  TaqMan              288/288        170     95         23          435    141    193   89    6     475    101    0.245

  Zheng           2017   China            Asian            PTB     PB                  TaqMan              1565/1509      1029    482        54          2540   590    997   467   45    2461   557    0.274
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

List of abbreviations: PTB: Pulmonary Tuberculosis; TB: Tuberculosis; EPTB: Extrapulmonary Tuberculosis; PCR-RFLP: PCR-Restriction fragment length polymorphism; ARMS-PCR: Amplification-refractory mutation system-PCR; TaqMan: probes used in quantitative PCR; T-ARMS-PCR: Multiplex Tetra-Primer Amplification Refractory Mutation System-PCR; MassARRAY: Non-fluorescent detection platform utilizing mass spectrometry to accurately measure PCR-derived amplicons.
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###### 

The pooled ORs and 95% CIs for the association between *P2X7* polymorphisms and tuberculosis susceptibility.

  Polymorphism   No.   Genetic Model    Association Test    Heterogeneity   Publication Bias Tests                                   
  -------------- ----- ---------------- ------------------- --------------- ------------------------ -------- ------ ------- ------- -------
  rs3751143      30    AC vs. AA        1.44 (1.17--1.78)   3.42            0.0006                   158.86   81.7   0.000   0.016   0.016
                       CC vs. AA        1.87 (1.40--2.49)   4.26            0.0004                   61.79    54.7   0.000   0.002   0.047
                       AC + CC vs. AA   1.50 (1.22--1.85)   3.78            0.0002                   178.85   83.8   0.000   0.007   0.018
                       CC vs. AC + AA   1.61 (1.25--2.07)   3.65            0.001                    50.79    44.9   0.005   0.006   0.051
                       C vs. A          1.41 (1.19--1.67)   3.97            \<0.0001                 173.41   83.3   0.000   0.006   0.066
  rs2393799      19    CT v CC          1.00 (0.83--1.20)   0.01            0.989                    32.34    44.3   0.020   0.460   0.753
                       TT vs. CC        0.99 (0.68--1.44)   0.04            0.965                    73.55    75.5   0.000   0.935   0.510
                       CT + TT vs. CC   0.97 (0.77--1.23)   0.22            0.825                    58.41    69.2   0.000   0.557   0.649
                       TT vs. CT + CC   0.99 (0.74--1.32)   0.08            0.938                    71.34    74.8   0.000   0.962   0.680
                       T vs. C          0.98 (0.83--1.17)   0.20            0.844                    95.15    81.1   0.000   0.657   0.763
  rs1718119      3     AG vs. GG        0.99 (0.86--1.13)   0.16            0.88                     1.13     0      0.57    0.308   0.602
                       AA vs. GG        0.70 (0.49--0.99)   1.99            0.05                     3.56     44     0.17    0.136   0.117
                       AG + AA vs. GG   0.96 (0.84--1.09)   0.68            0.50                     2.22     10     0.33    0.312   0.602
                       AA vs. AG + GG   0.70 (0.49--1.00)   1.98            0.05                     3.24     38     0.20    0.141   0.117
                       G vs. A          0.93 (0.83--1.04)   1.24            0.21                     3.49     43     0.17    0.242   0.602
  rs208294       3     AG vs. GG        1.03 (0.93--1.23)   0.89            0.37                     3.77     47     0.15    0.694   0.602
                       AA vs. GG        1.18 (0.69--2.02)   0.61            0.54                     8.99     78     0.010   0.900   0.602
                       AG + AA vs. GG   1.16 (0.80--1.68)   0.76            0.45                     6.50     69     0.04    0.751   0.602
                       AA vs. AG + GG   1.08 (0.78--1.49)   0.47            0.64                     5.60     64     0.06    0.904   0.602
                       A vs. G          1.09 (0.85--1.40)   0.70            0.49                     8.82     77     0.01    0.860   0.602
  rs7958311      2     AG vs. GG        1.01 (0.87--1.17)   0.09            0.93                     0.02     0      0.88            
                       AA vs. GG        1.23 (0.77--1.95)   0.87            0.38                     5.15     81     0.02            
                       AG + AA vs. GG   0.81 (0.50--1.31)   0.87            0.38                     8.09     88     0.004           
                       AA vs. AG + GG   1.24 (0.76--2.01)   0.87            0.38                     8.09     88     0.004           
                       A vs. G          1.11 (0.88--1.40)   0.87            0.38                     5.18     81     0.02            
  rs2230911      2     CG vs. CC        1.03 (0.90--1.19)   0.42            0.67                     0.95     0      0.33            
                       GG vs. CC        2.10 (0.58--7.66)   1.13            0.26                     6.65     85     0.010           
                       CG + GG vs. CC   1.01 (0.88--1.16)   0.13            0.89                     0.28     0      0.60            
                       GG vs. CG + CC   2.03 (0.60--6.94)   1.13            0.26                     6.12     84     0.01            
                       G vs. C          1.22 (0.83--1.80)   1.03            0.30                     6.09     84     0.01            

List of Abbreviations: OR: Odds Ratio; CI: Confidence interval Z: Z-score; P: Probability; χ2: χ2 test; I^2^: I^2^ value.
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###### 

Stratified analysis of P2X7 polymorphisms and tuberculosis risk.

  Parameters     No.   AC vs. AA           CC vs. AA   AC + CC vs. AA       CC vs. AC + AA   C vs. A                                                                     
  -------------- ----- ------------------- ----------- -------------------- ---------------- ------------------- ------- ------------------- ------- ------------------- --------
  rs3751143                                                                                                                                                              
  Tuberculosis                                                                                                                                                           
  PTB            21    1.35 (1.05--1.74)   0.020       1.50 (1.10--2.04)    0.010            1.39 (1.09--1.78)   0.009   1.34 (1.04--1.73)   0.020   1.31 (1.09--1.58)   0.004
  EPTB           9     1.68 (1.17--2.42)   0.005       2.62 (1.19--5.78)    0.020            1.84 (1.21--2.79)   0.004   2.05 (1.07--3.93)   0.030   1.67 (1.16--2.42)   0.006
  Ethnicities                                                                                                                                                            
  Asian          19    1.48 (1.09--2.00)   0.010       1.70 (1.17--2.48)    0.006            1.53 (1.13--2.06)   0.006   1.47 (1.07--2.00)   0.020   1.57 (1.22--2.02)   0.0005
  Caucasian      6     1.47 (0.99--2.17)   0.05        1.56 (0.70 − 3.51)   0.28             1.49 (0.98--2.26)   0.06    1.36 (0.70--2.66)   0.37    1.37 (0.96--1.97)   0.09
  African        3     1.45 (0.66--3.19)   0.36        2.16 (0.33--13.95)   0.42             1.60 (0.62--4.13)   0.33    1.89 (0.41--8.81)   0.42    1.56 (0.62--3.94)   0.35
  rs2393799            CT vs. CC           TT vs. CC   CT + TT vs. CC       TT vs. CT + CC   C vs. T                                                                     
  Asian          14    0.92 (0.74--1.14)   0.44        0.87 (0.54--1.41)    0.58             0.86 (0.66--1.14)   0.30    0.92 (0.61--1.40)   0.70    0.98 (0.83--1.17)   0.84
